95 related articles for article (PubMed ID: 16446090)
1. Synthesis and biological evaluation of 1-(2,4,5-trisubstituted phenyl)-3-(5-cyanopyrazin-2-yl)ureas as potent Chk1 kinase inhibitors.
Li G; Hasvold LA; Tao ZF; Wang GT; Gwaltney SL; Patel J; Kovar P; Credo RB; Chen Z; Zhang H; Park C; Sham HL; Sowin T; Rosenberg SH; Lin NH
Bioorg Med Chem Lett; 2006 Apr; 16(8):2293-8. PubMed ID: 16446090
[TBL] [Abstract][Full Text] [Related]
2. 1-(5-Chloro-2-alkoxyphenyl)-3-(5-cyanopyrazin-2-yl)ureas [correction of cyanopyrazi] as potent and selective inhibitors of Chk1 kinase: synthesis, preliminary SAR, and biological activities.
Wang GT; Li G; Mantei RA; Chen Z; Kovar P; Gu W; Xiao Z; Zhang H; Sham HL; Sowin T; Rosenberg SH; Lin NH
J Med Chem; 2005 May; 48(9):3118-21. PubMed ID: 15857116
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and in-vitro biological activity of macrocyclic urea Chk1 inhibitors.
Li G; Tao ZF; Tong Y; Przytulinska MK; Kovar P; Merta P; Chen Z; Zhang H; Sowin T; Rosenberg SH; Lin NH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6499-504. PubMed ID: 17931867
[TBL] [Abstract][Full Text] [Related]
4. Structure-based design, synthesis, and biological evaluation of potent and selective macrocyclic checkpoint kinase 1 inhibitors.
Tao ZF; Wang L; Stewart KD; Chen Z; Gu W; Bui MH; Merta P; Zhang H; Kovar P; Johnson E; Park C; Judge R; Rosenberg S; Sowin T; Lin NH
J Med Chem; 2007 Apr; 50(7):1514-27. PubMed ID: 17352464
[TBL] [Abstract][Full Text] [Related]
5. Macrocyclic ureas as potent and selective Chk1 inhibitors: an improved synthesis, kinome profiling, structure-activity relationships, and preliminary pharmacokinetics.
Tao ZF; Chen Z; Bui MH; Kovar P; Johnson E; Bouska J; Zhang H; Rosenberg S; Sowin T; Lin NH
Bioorg Med Chem Lett; 2007 Dec; 17(23):6593-601. PubMed ID: 17935989
[TBL] [Abstract][Full Text] [Related]
6. Discovery of 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-benzonitriles and 4'-(1,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-pyridine-2'-carbonitriles as potent checkpoint kinase 1 (Chk1) inhibitors.
Tao ZF; Li G; Tong Y; Stewart KD; Chen Z; Bui MH; Merta P; Park C; Kovar P; Zhang H; Sham HL; Rosenberg SH; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Nov; 17(21):5944-51. PubMed ID: 17827013
[TBL] [Abstract][Full Text] [Related]
7. Discovery of checkpoint kinase inhibitor (S)-5-(3-fluorophenyl)-N-(piperidin-3-yl)-3-ureidothiophene-2-carboxamide (AZD7762) by structure-based design and optimization of thiophenecarboxamide ureas.
Oza V; Ashwell S; Almeida L; Brassil P; Breed J; Deng C; Gero T; Grondine M; Horn C; Ioannidis S; Liu D; Lyne P; Newcombe N; Pass M; Read J; Ready S; Rowsell S; Su M; Toader D; Vasbinder M; Yu D; Yu Y; Xue Y; Zabludoff S; Janetka J
J Med Chem; 2012 Jun; 55(11):5130-42. PubMed ID: 22551018
[TBL] [Abstract][Full Text] [Related]
8. Synthesis and biological evaluation of 4'-(6,7-disubstituted-2,4-dihydro-indeno[1,2-c]pyrazol-3-yl)-biphenyl-4-ol as potent Chk1 inhibitors.
Tao ZF; Li G; Tong Y; Chen Z; Merta P; Kovar P; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem Lett; 2007 Aug; 17(15):4308-15. PubMed ID: 17544271
[TBL] [Abstract][Full Text] [Related]
9. Design, synthesis, and biological activity of 5,10-dihydro-dibenzo[b,e][1,4]diazepin-11-one-based potent and selective Chk-1 inhibitors.
Wang L; Sullivan GM; Hexamer LA; Hasvold LA; Thalji R; Przytulinska M; Tao ZF; Li G; Chen Z; Xiao Z; Gu WZ; Xue J; Bui MH; Merta P; Kovar P; Bouska JJ; Zhang H; Park C; Stewart KD; Sham HL; Sowin TJ; Rosenberg SH; Lin NH
J Med Chem; 2007 Aug; 50(17):4162-76. PubMed ID: 17658776
[TBL] [Abstract][Full Text] [Related]
10. Structure-based design, synthesis and biological evaluation of N-pyrazole, N'-thiazole urea inhibitors of MAP kinase p38α.
Getlik M; Grütter C; Simard JR; Nguyen HD; Robubi A; Aust B; van Otterlo WA; Rauh D
Eur J Med Chem; 2012 Feb; 48():1-15. PubMed ID: 22154891
[TBL] [Abstract][Full Text] [Related]
11. Optimization of a pyrazoloquinolinone class of Chk1 kinase inhibitors.
Brnardic EJ; Garbaccio RM; Fraley ME; Tasber ES; Steen JT; Arrington KL; Dudkin VY; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2007 Nov; 17(21):5989-94. PubMed ID: 17804227
[TBL] [Abstract][Full Text] [Related]
12. Development of thioquinazolinones, allosteric Chk1 kinase inhibitors.
Converso A; Hartingh T; Garbaccio RM; Tasber E; Rickert K; Fraley ME; Yan Y; Kreatsoulas C; Stirdivant S; Drakas B; Walsh ES; Hamilton K; Buser CA; Mao X; Abrams MT; Beck SC; Tao W; Lobell R; Sepp-Lorenzino L; Zugay-Murphy J; Sardana V; Munshi SK; Jezequel-Sur SM; Zuck PD; Hartman GD
Bioorg Med Chem Lett; 2009 Feb; 19(4):1240-4. PubMed ID: 19155174
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis and SAR of thienopyridines as potent CHK1 inhibitors.
Zhao L; Zhang Y; Dai C; Guzi T; Wiswell D; Seghezzi W; Parry D; Fischmann T; Siddiqui MA
Bioorg Med Chem Lett; 2010 Dec; 20(24):7216-21. PubMed ID: 21074424
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a novel class of 2-ureido thiophene carboxamide checkpoint kinase inhibitors.
Janetka JW; Almeida L; Ashwell S; Brassil PJ; Daly K; Deng C; Gero T; Glynn RE; Horn CL; Ioannidis S; Lyne P; Newcombe NJ; Oza VB; Pass M; Springer SK; Su M; Toader D; Vasbinder MM; Yu D; Yu Y; Zabludoff SD
Bioorg Med Chem Lett; 2008 Jul; 18(14):4242-8. PubMed ID: 18547806
[TBL] [Abstract][Full Text] [Related]
15. Discovery of 1,4-dihydroindeno[1,2-c]pyrazoles as a novel class of potent and selective checkpoint kinase 1 inhibitors.
Tong Y; Claiborne A; Stewart KD; Park C; Kovar P; Chen Z; Credo RB; Gu WZ; Gwaltney SL; Judge RA; Zhang H; Rosenberg SH; Sham HL; Sowin TJ; Lin NH
Bioorg Med Chem; 2007 Apr; 15(7):2759-67. PubMed ID: 17287122
[TBL] [Abstract][Full Text] [Related]
16. Structure-guided evolution of potent and selective CHK1 inhibitors through scaffold morphing.
Reader JC; Matthews TP; Klair S; Cheung KM; Scanlon J; Proisy N; Addison G; Ellard J; Piton N; Taylor S; Cherry M; Fisher M; Boxall K; Burns S; Walton MI; Westwood IM; Hayes A; Eve P; Valenti M; de Haven Brandon A; Box G; van Montfort RL; Williams DH; Aherne GW; Raynaud FI; Eccles SA; Garrett MD; Collins I
J Med Chem; 2011 Dec; 54(24):8328-42. PubMed ID: 22111927
[TBL] [Abstract][Full Text] [Related]
17. Hsp90-inhibitor geldanamycin abrogates G2 arrest in p53-negative leukemia cell lines through the depletion of Chk1.
Sugimoto K; Sasaki M; Isobe Y; Tsutsui M; Suto H; Ando J; Tamayose K; Ando M; Oshimi K
Oncogene; 2008 May; 27(22):3091-101. PubMed ID: 18071310
[TBL] [Abstract][Full Text] [Related]
18. 3-(Indol-2-yl)indazoles as Chek1 kinase inhibitors: Optimization of potency and selectivity via substitution at C6.
Fraley ME; Steen JT; Brnardic EJ; Arrington KL; Spencer KL; Hanney BA; Kim Y; Hartman GD; Stirdivant SM; Drakas BA; Rickert K; Walsh ES; Hamilton K; Buser CA; Hardwick J; Tao W; Beck SC; Mao X; Lobell RB; Sepp-Lorenzino L; Yan Y; Ikuta M; Munshi SK; Kuo LC; Kreatsoulas C
Bioorg Med Chem Lett; 2006 Dec; 16(23):6049-53. PubMed ID: 16978863
[TBL] [Abstract][Full Text] [Related]
19. Synthesis and evaluation of triazolones as checkpoint kinase 1 inhibitors.
Oza V; Ashwell S; Brassil P; Breed J; Ezhuthachan J; Deng C; Grondine M; Horn C; Liu D; Lyne P; Newcombe N; Pass M; Read J; Su M; Toader D; Yu D; Yu Y; Zabludoff S
Bioorg Med Chem Lett; 2012 Mar; 22(6):2330-7. PubMed ID: 22342147
[TBL] [Abstract][Full Text] [Related]
20. Synthesis of selenophene derivatives as novel CHK1 inhibitors.
Hong PC; Chen LJ; Lai TY; Yang HY; Chiang SJ; Lu YY; Tsai PK; Hsu HY; Wei WY; Liao CB
Bioorg Med Chem Lett; 2010 Sep; 20(17):5065-8. PubMed ID: 20674356
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
